Cover of: Reexamining Drug Regulation from the Perspective of Innovation Policy: Comment
Peter Zweifel

Reexamining Drug Regulation from the Perspective of Innovation Policy: Comment

Section: Articles
Volume 160 (2004) / Issue 1, pp. 136-141 (6)
Published 09.07.2018
DOI 10.1628/093245604773861177
  • article PDF
  • available
  • 10.1628/093245604773861177
Summary
This is a very colorful paper that makes for interesting reading. The author shows that the U. S. Food and Drug Administration (FDA) increasingly does not decide about market access to drugs only, but influences the innovation process as a whole. And although »information« does not appear in the title of the paper, the distribution of knowledge as affected by the FDA plays an important role at several stages of this process. For this reason, the body of this commentary is arranged according to the stages of the innovation process.